NCT06254261 A Study of RAY1225 in Participants With Obesity
| NCT ID | NCT06254261 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 270 participants |
| Start Date | 2024-02-21 |
| Primary Completion | 2025-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 270 participants in total. It began in 2024-02-21 with a primary completion date of 2025-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
Eligibility Criteria
Inclusion Criteria: 1. Have a body mass index (BMI) of ≥28 kilogram per square meter (kg/m²) or ≥24 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease,or HbA1c ≥5.7% and \< 6.5%; 2. Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product. Exclusion Criteria: 1. Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity 2. with a history of diabetes or hypoglycemia; 3. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator. 4. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening) 5. allergic constitution; 6. not suitable for subcutaneous injection.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06254261 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06254261 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06254261 currently recruiting?
Yes, NCT06254261 is actively recruiting participants. Contact the research team at iao@pkuph.edu.cn for enrollment information.
Where is the NCT06254261 trial being conducted?
This trial is being conducted at Beijingcun, China.
Who is sponsoring the NCT06254261 clinical trial?
NCT06254261 is sponsored by Guangdong Raynovent Biotech Co., Ltd. The trial plans to enroll 270 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.